RINVOQ 15 mg, comprimé à libération prolongée

EUEMA:by INNUSDailyMed:Upadacitinib AU:DNot recommended L04AF03(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide 1310726-60-3Y 58557659 9246 DB15091Y 44210449Y 4RA0KN46E0 D10994YD11048Y ChEMBL3622821Y DTXSID901027919 Interactive image CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cn​‍​​​​​‍​‍‍‍‍​‍‍c3[nH]ccc3n12 InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1YKey:WYQFJHHDOKWSHR-MNOVXSKESA-NY Upadacitinib, sold under the brand nameRinvoq, is a medication used for the treatment ofrheumatoid arthritis,psoriatic arthritis,atopic dermatitis,ulcerative colitis,Crohn's disease,ankylosing spondylitis, andaxial spondyloarthritis.Upadacitinib is aJanus kinase (JAK) inhibitorthat works by blocking the action of enzymes calledJanus kinases.These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. Upadacitinib was approved for medical use in both the United States and the European Union in 2019.